Elstar Therapeutics President and CEO Steve Arkinstall featured on Bloomberg Radio’s Baystate Business Hour

Cambridge, MA, May June 14, 2018—Bloomberg Baystate Business Hour program featured Steve Arkinstall, Elstar Therapeutics’ President and CEO in their weekly C-suite interview segment. Steve talked about the advantages of Elstar’s multi-functional antibody-like therapeutics. Built with its proprietary UniTI technology, these molecules are fulfilling the promise of precision cancer immunotherapy by harnessing potent tumor-targeted immune engagement without systemic toxicities. As a cancer survivor himself, Steve additionally discussed his first-hand experience with some of the earliest cancer immunotherapies, and the strong passion for improving cancer care that stemmed from that.

You can listen to the discussion at the link below.


About Elstar Therapeutics, Inc.

Elstar Therapeutics is fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating antibody-based, multi-functional therapeutics.

Armed with a unique approach to engaging multiple immune mechanisms, Elstar enables patients to harness their own body to fight cancer.

Elstar’s Universal Targeted Immunotherapy (UniTI™) platform is positioned to overcome barriers that are limiting the full potential of other promising immunotherapeutic approaches.

“Our motivation…to be part of the cure for cancer.”